FDA Proposes Metastasis-Free Survival Endpoint in Prostate Cancer Trials

Drug Industry Daily
A A
The FDA Tuesday issued draft guidance for clinical trial sponsors of treatments for a rare form of prostate cancer — nonmestastatic, castration-resistant prostate cancer (nmCRPC) — and said it will consider metastasis-free survival as an endpoint.

To View This Article:

Login

Subscribe To Drug Industry Daily